Use of surface EMG for evaluation of upper limb spasticity during botulinum toxin therapy in stroke patients

Functional Neurology

Volumn 25, Issue 2, 2010, Pages 103-107

  Albani, Giovanni ^a,b   Cimolin, Veronica ^c   Galli, Manuela ^c   Vimercati, Sara ^c   Bar, Daniela ^a,b   Campanelli, Laura ^a,b   Gandolfi, Roberto ^d   Lombardi, Remo ^d   Mauro, Alessandro ^a,b  

^a UNIVERSITY OF TURIN   (Italy)

^b ISTITUTO AUXOLOGICO ITALIANO   (Italy)

^c POLITECNICO DI MILANO   (Italy)

^d UNIVERSITY OF PAVIA   (Italy)

Author keywords

Botulinum toxin; Electromyography; Spasticity; Stroke; Upper limb

Indexed keywords

BOTULINUM TOXIN A;

ADULT; AGED; ARM; ARTICLE; CLINICAL ARTICLE; DRUG EFFECT; DRUG EFFICACY; DRUG RESPONSE; ELECTROMYOGRAPHY; FEMALE; FUNCTIONAL ASSESSMENT; GENERAL CONDITION IMPROVEMENT; HUMAN; MALE; SPASTICITY; STROKE; TREATMENT OUTCOME;

ADULT; AGED; BOTULINUM TOXINS, TYPE A; ELECTROMYOGRAPHY; FEMALE; HUMANS; LONGITUDINAL STUDIES; MALE; MIDDLE AGED; MUSCLE SPASTICITY; NEUROMUSCULAR AGENTS; PAIN MEASUREMENT; RANGE OF MOTION, ARTICULAR; SEVERITY OF ILLNESS INDEX; STROKE; TREATMENT OUTCOME; UPPER EXTREMITY;

EID: 77957652568     PISSN: 03935264     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (24)

1. Sacco S, Cerone D, Carolei A. Gender and stroke: acute phase treatment and prevention. Funct Neurol 2009;24:45-52
2. Bhakta BB, Cozens JA, Bamford JM, Chamberlain MA. Use of botulinum toxin in stroke patients with severe upper limb spasticity. J Neurol Neurosurg Psychiatry 1996;61:30-35
3. Simpson DM, Alexander DN, O'Brien CF et al. Botulinum toxin type A in the treatment of upper extremity spasticity: a randomised, double-blind, placebo-controlled trial. Neurology 1996;46:1306-1310
4. Ahnert-Hilger G, Bigalke H. Molecular aspects of tetanus and botulinum neurotoxin poisoning. Prog Neurobiol 1995;46:83-96
5. Blasi J, Chapman ER, Link E et al. Botulinum neurotoxin A selectively cleaves the synaptic protein SNAP-25. Nature 1993;365:160-163
6. Dolly J, de Paiva A, Foran P, Lawrence G, Daniels-Holgate P, Ashton A. Probing the process of transmitter release with botulinus and tetanus neurotoxin. Semin Neurosci 1944;6:149-158
7. Borodic GE, Ferrante R, Pearce LB, Smith K. Histologic assessment of dose-related diffusion and muscle fiber response after therapeutic botulinum A toxin injection. Mov Disord 1994;9:31-39
8. Bakheit AM. Optimising the methods of evaluation of the effectiveness of botulinum toxin treatment of post-stroke muscle spasticity. J Neurol Neurosurg Psychiatry 2004;75:665-666
9. Brashear A, Gordon MF, Elovic E et al. Intramuscular injection of botulinum toxin for the treatment of wrist and finger spasticity after a stroke. N Eng J Med 2002;347:395-400
10. Panizza M, Castagna M, di Summa A, Saibene L, Grioni G, Nilsson J. Functional and clinical changes in upper limb spastic patients treated with botulinum toxin (BTX). Funct Neurol 2000;15:147-155
11. Bhakta BB, Cozens JA, Chamberlain MA, Bamford JM. Impact of botulinum toxin type A on disability and carer burden due to arm spasticity after stroke: a randomised double blind placebo controlled trial. J Neurol Neurosurg Psychiatry 2000;69:217-221
12. Richardson D, Sheean G, Werring D et al. Evaluating the role of botulinum toxin in the management of focal hypertonia in adults. J Neurol Neurosurg Psychiatry 2000;69:499-506
13. Wissel J, Müller J, Dressnandt J et al. Management of spasticity associated pain with botulinum toxin A. J Pain Symptom Manage 2000;20:44-49
14. Pandyan AD, Vuadens P, van Wijck FM et al. Are we under-estimating the clinical efficacy of botulinum toxin (type A)? Quantifying changes in spasticity, strength and upper limb function after injections of Botox to the elbow flexors in a unilateral stroke population. Clin Rehabil 2002;16:654-660
15. Pierson SH. Outcome measures in spasticity management. Muscle Nerve Suppl 1997;6:S36-S60
16. Turner-Stokes L, Ashford S. Serial injection of botulinum toxin for muscle imbalance due to regional spasticity in the upper limb. Disabil Rehabil 2007;29:1806-1812
17. Kiresuk T, Sherman R. Goal attainment scaling: a general method of evaluating comprehensive mental health programmes. Commun Ment Health J 1968;4:443-453
18. Cousins E, Ward AB, Roffe C, Rimington LD, Pandyan AD. Quantitative measurement of poststroke spasticity and response to treatment with botulinum toxin: a 2-patient case report. Phys Ther 2009;89:688-697
19. Kendall FP, McCreary EK, Provance PG. Muscles: Testing and Function. 4th ed. Baltimore; Williams & Wilkins 1993
20. Bohannon RW, Smith MB. Interrater reliability of a modified Ashworth scale of muscle spasticity. Phys Ther 1987;67:206-207
21. Hermens H, Freriks B, Merletti R et al. SENIAM. Raccomandazioni Europee per l'Elettromiografia di Superficie. Turin; CLUT Editrice 2000
22. Bakheit AM, Pittok S, Moore AP, Wurker M, Otto S, Erbguth F, Coxon L. A randomized, double-blind, placebo-controlled study of the efficacy and safety of botulinum toxin type A in upper limb spasticity in patients with stroke. Eur J Neurol 2001;8:559-565
23. Grazko MA, Polo KB, Jabbari B. Botulinum toxin A for spasticity, muscle spasms, and rigidity. Neurology 1995;45:712-717
24. Aoki KR. Review of a proposed mechanism for the antinociceptive action of botulinum toxin type A. Neurotoxicology 2005;26:785-793